Nicole Fram, MD
Ophthalmology · Los Angeles, CANPI 1114140795
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $429,253 of the $551,236 with a category attached, or 77.9%. 42 manufacturers reported payments, led by Alcon at 34.2% of the total. 2025 is the largest year on record at $242,677, 8.2 times the $29,450 reported in 2019. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 789 payments — averaging $698.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$189K
- Beaver-visitec International, Inc.$106K
- Alcon Research LLC$53K
- Tarsus Pharmaceuticals, Inc.$52K
- Johnson & Johnson Surgical Vision, Inc.$36K
- Carl Zeiss Meditec, Inc.$19K
- plus $97K from 36 others
Across 86 payments — averaging $7972.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$472K
- Alcon Research LLC$98K
- AbbVie$63K
- Carl Zeiss Meditec, Inc.$50K
- Bausch & Lomb Americas Inc.$2K
What the payments were for
- Consulting fees$429,25378%
- Speaking & faculty fees$80,82315%
- Travel & lodging$9,5182%
- Food & beverage$29,1415%
- Charitable contribution$2,5000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Centurion$67,996
- Clareon$66,582
- XDEMVY$37,939
- AcrySof IQ PanOptix UV IOL$36,461
- Tecnis IOL$36,279
- AcrySof IQ VIVITY$20,177
- Wavelight Refractive Suite$20,150
- Unity$19,801
- LIPIFLOW SYSTEM ACTIVATOR (DISPOSABLE)$17,600
- Whitestar Signature$17,600
- AcrySof$15,824
- VERACITY SURGICAL$15,726
- AcrySof IQ PanOptix$14,710
- AcrySof IQ VIVITY IOL$12,400
- WaveLight EX500 Excimer Laser$10,750
- XIIDRA$10,588
- AcrySof Toric Aspheric UV Absorbing IOL$10,450
- Tecnis Simplicity$10,040
- TRYPTYR$8,645
- QUATERA 700$8,637
How this compares
$551,236 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 148 | $123,401 |
| ProlensaBromfenac Sodium | 200 | $68,131 |
| XiidraLifitegrast | 40 | $39,597 |
| XdemvyLotilaner | 21 | $39,405 |
| MieboPerfluorohexyloctane/Pf | 43 | $32,635 |
| Bromfenac Sodium | 179 | $31,942 |
| Prednisolone Acetate | 584 | $29,441 |
| Cyclosporine | 86 | $20,309 |
| Lotemax SmLoteprednol Etabonate | 73 | $19,466 |
| CombiganBrimonidine Tartrate/Timolol | 26 | $14,231 |
| LumiganBimatoprost | 19 | $12,283 |
| Loteprednol Etabonate | 90 | $11,676 |
| IlevroNepafenac | 32 | $11,606 |
| CequaCyclosporine | 16 | $11,585 |
| MoxifloxacinMoxifloxacin Hcl | 551 | $10,948 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Lumigan, Restasis Multidose, Alphagan P | $13,965 | $162,481220 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm, Loteprednol Etabonate, Lotemax | $5,137 | $103,962377 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $2,971 | $72,23283 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $52,241 | $39,40521 claims |
| NovartisIlevro | $6,723 | $11,60632 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,351 | $11,58516 claims |
| AlconSimbrinza | $188,509 | $4,79721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Los Angeles
- Andrew MoshfeghiLos Angeles$895K
- Barry SeibelLos Angeles$835K
- Neda ShamieLos Angeles$547K
- David BoyerLos Angeles$406K
- David HamiltonLos Angeles$359K
- Arjan HuraLos Angeles$306K
- Firas RahhalLos Angeles$264K
- Kouros NourimahdaviLos Angeles$258K
- Daniel RootmanLos Angeles$247K
- Amy JainLos Angeles$233K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.